| Guidelines for the use and interpretation of assays for monitoring autophagy DJ Klionsky, K Abdelmohsen, A Abe, MJ Abedin, H Abeliovich, ... Autophagy 12 (1), 1-222, 2016 | 14928* | 2016 |
| A Phase 3 trial of Bevacizumab in Ovarian Cancer TJ Perren, AM Swart, J Pfisterer, JA Ledermann, E Pujade-Lauraine, ... New England Journal of Medicine 365 (26), 2484-2496, 2011 | 2895 | 2011 |
| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet 390 (10106), 1949-1961, 2017 | 1934 | 2017 |
| Rethinking ovarian cancer: recommendations for improving outcomes S Vaughan, JI Coward, RC Bast Jr, A Berchuck, JS Berek, JD Brenton, ... Nature Reviews Cancer 11 (10), 719-725, 2011 | 1628 | 2011 |
| ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease N Colombo, C Sessa, A du Bois, J Ledermann, WG McCluggage, ... International Journal of Gynecological Cancer 29 (4), 728-760, 2019 | 1522 | 2019 |
| Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer DD Bowtell, S Böhm, AA Ahmed, PJ Aspuria, RC Bast Jr, V Beral, ... Nature reviews Cancer 15 (11), 668-679, 2015 | 1415 | 2015 |
| Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial EM Swisher, KK Lin, AM Oza, CL Scott, H Giordano, J Sun, GE Konecny, ... The lancet oncology 18 (1), 75-87, 2017 | 1321 | 2017 |
| “Re-educating” tumor-associated macrophages by targeting NF-κB T Hagemann, T Lawrence, I McNeish, KA Charles, H Kulbe, ... The Journal of experimental medicine 205 (6), 1261-1268, 2008 | 1011 | 2008 |
| Paraneoplastic thrombocytosis in ovarian cancer RL Stone, AM Nick, IA McNeish, F Balkwill, HD Han, J Bottsford-Miller, ... New England Journal of Medicine 366 (7), 610-618, 2012 | 970 | 2012 |
| A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor JCC Hu, RS Coffin, CJ Davis, NJ Graham, N Groves, PJ Guest, ... Clinical cancer research 12 (22), 6737-6747, 2006 | 724 | 2006 |
| Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer CM Phelan, KB Kuchenbaecker, JP Tyrer, SP Kar, K Lawrenson, ... Nature genetics 49 (5), 680-691, 2017 | 528 | 2017 |
| Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer B Delage, DA Fennell, L Nicholson, I McNeish, NR Lemoine, T Crook, ... International journal of cancer 126 (12), 2762-2772, 2010 | 506 | 2010 |
| Interleukin-6 as a therapeutic target in human ovarian cancer J Coward, H Kulbe, P Chakravarty, D Leader, V Vassileva, DA Leinster, ... Clinical cancer research 17 (18), 6083-6096, 2011 | 500 | 2011 |
| Copy number signatures and mutational processes in ovarian carcinoma G Macintyre, TE Goranova, D De Silva, D Ennis, AM Piskorz, M Eldridge, ... Nature genetics 50 (9), 1262-1270, 2018 | 487 | 2018 |
| Mannose impairs tumour growth and enhances chemotherapy PS Gonzalez, J O’Prey, S Cardaci, VJA Barthet, J Sakamaki, F Beaumatin, ... Nature 563 (7733), 719-723, 2018 | 468 | 2018 |
| Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian … O Kondrashova, M Nguyen, K Shield-Artin, AV Tinker, NNH Teng, ... Cancer discovery 7 (9), 984-998, 2017 | 448 | 2017 |
| BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma KK Lin, MI Harrell, AM Oza, A Oaknin, I Ray-Coquard, AV Tinker, ... Cancer discovery 9 (2), 210-219, 2019 | 438 | 2019 |
| A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45) BJ Monk, C Parkinson, MC Lim, DM O'malley, A Oaknin, MK Wilson, ... Journal of Clinical Oncology 40 (34), 3952-3964, 2022 | 378 | 2022 |
| New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation S Vandevyver, L Dejager, J Tuckermann, C Libert Endocrinology 154 (3), 993-1007, 2013 | 378 | 2013 |
| Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials I Vergote, C Coens, M Nankivell, GB Kristensen, MKB Parmar, T Ehlen, ... The Lancet Oncology 19 (12), 1680-1687, 2018 | 358 | 2018 |
Yaohe WangBarts Cancer Institute Queen Mary University of LondonVerified email at qmul.ac.uk
